Clene Nanomedicine

CLNN · Nasdaq · United States

Share price · CLNN

$3.42-0.67 (-16.38%) 3M

close as of 2026-11-18 · 24h delayed · vol 240K (2.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CLNN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-12.0%
  2. 15 Sep 2026+22.6%
  3. 14 Sep 2026-8.1%

    Nothing announced by CLNN that day or the session before.

  4. 12 Aug 2026-6.9%

    Nothing announced by CLNN that day or the session before.

  5. 11 Aug 2026-15.3%
  6. 5 May 2026-18.7%
  7. 4 May 2026+31.8%
  8. 6 Apr 2026+12.5%

    Nothing announced by CLNN that day or the session before.

  9. 19 Mar 2026-10.7%
  10. 29 Jan 2026-15.1%

    Nothing announced by CLNN that day or the session before.

Share of unusual movement by asset

For each asset, the share of CLNN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
CNM-Au8
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—66%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
mitochondrial energy metabolismOther
Parkinson's DiseaseMultiple SclerosisAmyotrophic Lateral Sclerosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026Filing submittedCNM-Au8Clene submits an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS
US, FDA · Clene Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.1M$4.5M$9.9M+ <$0.1M short-term inv.—-$4.6M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.1M$3.5M$9.7M+ <$0.1M short-term inv.$13M-$2.6M operating cash flowreport ↗
2026-Q1<$0.1M$0.3M$6.0M$8.1M-$4.5M operating cash flowreport ↗
2025-Q3<$0.1M$3.5M$8.0M$8.8M-$4.0M operating cash flowreport ↗
2025-Q2<$0.1M$3.5M$7.3M+ <$0.1M short-term inv.$7.4M-$4.7M operating cash flowreport ↗
2025-Q1$0.1M$1.5M$9.9M$0.8M-$5.0M operating cash flowreport ↗
2024-Q3$0.1M$4.5M$15M+ $0 short-term inv.$8.0M-$3.0M operating cash flowreport ↗
2024-Q2$0.1M$4.2M$22M+ $0 short-term inv.$6.8M-$6.4M operating cash flowreport ↗
2024-Q1$0.1M$5.9M$22M+ $6.2M short-term inv.$11M-$7.1M operating cash flowreport ↗
2023-Q3$0.1M$6.0M$42M+ $0 short-term inv.$2.4M-$6.8M operating cash flowreport ↗
2023-Q2$0.3M$6.6M$49M+ $0 short-term inv.$25M-$7.0M operating cash flowreport ↗
2023-Q1$0.1M$7.4M$19M+ $0 short-term inv.$12M-$9.2M operating cash flowreport ↗
2022-Q3$0.2M$6.4M$7.3M+ $9.0M short-term inv.$11M-$8.5M operating cash flowreport ↗
2022-Q2<$0.1M$9.2M$7.3M+ $19M short-term inv.$4.5M-$9.7M operating cash flowreport ↗
2022-Q1<$0.1M$8.6M$13M+ $24M short-term inv.$13M-$13M operating cash flowreport ↗
2021-Q3$0.1M$6.2M$61M—-$7.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.2M$14M$5.3M+ <$0.1M short-term inv.$6.5M-$19M operating cash flowreport ↗

For fiscal year 2025, Clene reported revenue of $0.2M, down 41.2% YoY, with R&D spend of $14.01M, down 30.2% YoY. Cash and equivalents stood at $5.25M, and the company reported a net loss of $26.17M, with a disclosed quarterly net burn of $26.17M.

The 10-K describes ongoing CNM-Au8 clinical programs in amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease, along with regulatory activities for CNM-Au8 and CNM-ZnAg nonclinical work. The filing also discloses material weaknesses in internal control over financial reporting and notes a subsequent January 2026 public equity offering.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.3M$20M$12M+ $0 short-term inv.$9.8M-$21M operating cash flowreport ↗
2023-FY$0.7M$27M$29M+ $6.2M short-term inv.$12M-$30M operating cash flowreport ↗
2022-FY$0.5M$32M$18M+ $5.0M short-term inv.$7.5M-$39M operating cash flowreport ↗
2021-FY$0.7M$28M$50M+ $0 short-term inv.$2.4M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($251K), 62 sales ($5.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18WILCOX REED N · directorOpen-market purchase8,000$3.42$27KForm 4
2026-11-18WILCOX REED N · directorOpen-market purchase2,000$3.44$7KForm 4
2026-11-12WILCOX REED N · directorAward / grant (derivative)3,395——Form 4
2026-11-12McLaughlin Vallerie · directorAward / grant (derivative)3,395——Form 4
2026-11-12Gay Jonathon · directorAward / grant (derivative)3,665——Form 4
2026-11-12MATLIN DAVID J · directorAward / grant (derivative)6,019——Form 4
2026-11-12Kiernan Matthew · directorAward / grant (derivative)3,086——Form 4
2026-11-12Mosca Alison · director, 10% ownerAward / grant (derivative)4,707——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 29 reporting institutions held 2.2M shares ($10.8M, 15.6% of shares outstanding).

#InstitutionSharesValue
1Boxer Capital Management, LLC477,515$2.4M
2SymBiosis Capital Partners, LLC431,094$2.1M
3VANGUARD CAPITAL MANAGEMENT LLC308,230$1.5M
4SCOGGIN MANAGEMENT LP300,000$1.5M
5Ensign Peak Advisors, Inc257,872$1.3M
6GEODE CAPITAL MANAGEMENT, LLC95,874$473K
7Lunt Capital Management, Inc.52,260$258K
8PEAK6 LLC50,012$247K
9VANGUARD FIDUCIARY TRUST CO43,715$216K
10PARSONS CAPITAL MANAGEMENT INC/RI37,243$184K
11BlackRock, Inc.33,799$167K
12STATE STREET CORP29,801$147K
13MORGAN STANLEY19,832$98K
14NORTHERN TRUST CORP16,143$80K
15PENN DAVIS MCFARLAND INC11,000$54K